[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sustained-vt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sustained-vt":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100491187","cryoablation-for-monomorphic-ventricular-tachycardia-100491187",false,"NCT05675865","Cryoablation for Monomorphic Ventricular Tachycardia","Cryoablation for Monomorphic Ventricular Tachycardia IDE Study: EFS and Pivotal","FULCRUM-VT","Inclusion Criteria (IC):\n\n* IC 1 Male or female ≥ 18 years\n* IC 2 Patients with a clinical indication for catheter ablation due to ischemic and\u002For non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.\n* IC 3 Any of the following:\n\n  * Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF \\\u003C 50%.\n  * non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF \\\u003C 50%\n  * Arrhythmogenic right ventricular cardiomyopathy (ARVC)\n* IC 4 Has received a market-released ICD prior to enrollment\n* IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months\n* IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated\u002F desired due to side effects)\n* IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study\n* IC 8 Willingness and ability to give an informed consent\n\nExclusion Criteria (EC):\n\n* EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure\n* EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use\n* EC 3 VTs due to any of the following causes:\n\n  1. Idiopathic VT\n  2. Automaticity or triggered activity\n  3. Bundle Branch Reentry (BBR)\n  4. Any focal tachycardia (e.g., papillary, RVOT)\n  5. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause\n* EC 4 NICM patients only, if any of the following apply:\n\n  1. Congenital condition that limits access to the left or right ventricles\n  2. Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency\n  3. Active inflammatory processes (e.g., myocarditis) within the past 120 days\n  4. Sarcoidosis\n  5. Hypertrophic cardiomyopathy\n  6. Drug- or alcohol-induced cardiomyopathy\n* EC 5 Any VT ablation within 4 weeks prior to enrollment\n* EC 6 More than one prior (\\>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years\n* EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT\n* EC 8 Any other cardiovascular conditions as described below:\n\n  1. Class IV heart failure\n  2. Aortic aneurysm\n  3. Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure\n  4. Interatrial baffle, closure device, patch, or PFO occlusion device\n  5. Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure\n  6. Acute MI or unstable angina in the previous 60 days\n  7. Mechanical mitral or aortic valve\n  8. Cardiac myxoma\n  9. Significant congenital heart disease\n* EC 9 Acute illness or active systemic infection\n* EC 10 Any previous history of cryoglobulinemia\n* EC 11 History of blood clotting or bleeding disease\n* EC 12 Peripheral vascular disease that precludes LV access\n* EC 13 Contraindication to heparin\n* EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure\n* EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.\n* EC 16 Pregnant, or anticipated pregnancy during study follow-up\n* EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study\n* EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)","ALL","18 Years",{"count":20,"type":21},206,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)",[27],"Sustained VT",[29,30,31],"cryoablation","monomorphic VT","sustained monomorphic VT","RECRUITING","2026-04-02",{"date":35,"type":36},"2026-04-07","ACTUAL",{"date":38,"type":36},"2023-09-11",{"date":40,"type":21},"2027-03-30",{"name":42,"class":43},"Adagio Medical","INDUSTRY",15,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100584600","pulsed-field-ablation-for-post-infarction-ventricular-tachycardia-100584600","NCT06891456","Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia","Pulse Field Ablation for Post-Infarction Ventricular Tachycardia: the ASCEND Pilot Study","ASCEND-VT","Inclusion Criteria: must meet all of the following:\n\n1. Age ≥18 years.\n2. Ischemic heart disease with prior myocardial infarction.\n3. Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment.\n4. Documented sustained monomorphic VT with any of the following characteristics:\n\n   1. ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD)\n   2. ≥1 documented episode(s) in patients without ICD\n   3. Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions\n5. Provision of signed and dated informed consent form.\n6. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria: any of the following:\n\n1. Unable to provide informed consent.\n2. Idiopathic VT.\n3. Mobile LV thrombus.\n4. Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment).\n5. Comorbidity likely to limit survival to \\\u003C12 months\n6. New York Heart Association class IV heart failure.\n7. Estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2.\n8. Thrombocytopenia or coagulopathy.\n9. Contraindication to heparin.\n10. Pregnancy or lactation.\n11. Cardiac surgery within the past 2 months.\n12. Active infection.\n13. Clinical, laboratory or imaging evidence of active ischemia.\n14. Severe left heart valvular heart disease (aortic\u002Fmitral stenosis or regurgitation).\n15. Any concomitant congenital heart disease.\n16. Prior catheter or surgical ablation of VT within the past 2 months.\n17. Anticipated need for epicardial mapping and ablation.\n18. For individuals with no pre-existing ICD: Ineligibility for an ICD implant.\n19. Pre-existing LVAD or other hemodynamic assist device\n20. Present mechanical heart valve\n21. cardiogenic shock unless it is due to incessant VT",{"count":54,"type":21},40,[24],"ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST\u002FFlexAbility SE\u002FThermoCool ST SF\u002FTactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.",[58,59,27],"Ventricular Tachycardia","Ischemic Heart Disease","2025-08-14",{"date":62,"type":36},"2025-08-19",{"date":64,"type":36},"2025-06-16",{"date":66,"type":21},"2028-12-31",{"name":68,"class":69},"Pasquale Santangeli","OTHER",1]